title: Integrating incretin-based therapy into type 2 diabetes management.
authors.affiliation: Department of Family Medicine, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Brunton
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000378:metabolism*; D000069450:Liraglutide; D055118:Medication Adherence; D010455:Peptides / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018027:Receptors, Glucagon / Q000819:agonists; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide